What do you recommend for patients with stage 3 MSI-H colorectal cancer who are ineligible for oxaliplatin-based adjuvant therapy?  

I typically don’t offer adjuvant therapy to those patients. 5-Fu/Xeloda does not benefit as a single agent in this patient population. If Oxaliplatin-based treatments cannot be given, then there are practically no other options that are associated with a survival benefit. 

Similar questions on this topic have come up more than once on theMednet. Unfortunately, we still do not have any results from the two phase III randomized trials to guide immunotherapy in this setting. While we have data showing quite impressive results with immune checkpoint inhibitors in MSI-H/dM...

I would identify those patients early and adopt a peri-op approach rather than go for surgery and face this dilemma. The alternative is enrolling in a clinical trial if available. I have tried adjuvant single and dual ICI in these settings but my limited experience wasn't overtly positive (ctDNA an...

I would definitely try to obtain approval for doublet immunotherapy in this setting. Would obtain pre-treatment ctDNA (also not standard of care) and stop after six months. I remember that we offered immunotherapy in stage four MSI/dMMR only after progressing on first-line chemotherapy. I hope that ...